Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.495, 2006-01, pp. : 8-8
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
PEG IFN-α-2b/ribavirin cost effective for HIV/HCV co-infection
Inpharma, Vol. 1, Iss. 1522, 2006-01 ,pp. :
Access to resources
Recommend
PEG IFN- -2b + ribavirin superior for HCV + HIV infection
Inpharma, Vol. 1, Iss. 1469, 2005-01 ,pp. :
PEG IFN- -2a/ribavirin a good pick for HCV in HIV/HCV coinfection
Inpharma, Vol. 1, Iss. 1430, 2004-01 ,pp. :
Evaluating EVR to PEG IFN-α-2b/ribavirin therapy worthwhile
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 491, 2005-01 ,pp. :
PEG IFN- -2a/ribavirin superior to IFN- -2a/ribavirin in HCV + HIV
Inpharma, Vol. 1, Iss. 1449, 2004-01 ,pp. :